95 related articles for article (PubMed ID: 2159428)
21. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.
Selle F; Pautier P; Lhommé C; Viens P; Fabbro M; Lokiec F; Gligorov J; Richard S; Provent S; Soares DG; Lotz JP
Chemotherapy; 2016; 61(1):15-22. PubMed ID: 26528705
[TBL] [Abstract][Full Text] [Related]
22. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of radiotherapy for state I ovarian carcinoma].
Sheng X; Sun J; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):314-6. PubMed ID: 9387332
[TBL] [Abstract][Full Text] [Related]
24. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities.
Kaern J; Tropé CG; Abeler VM
Cancer; 1993 Mar; 71(5):1810-20. PubMed ID: 8383580
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Wils JA
Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy in the management of ovarian germ cell malignancies.
Schwartz PE
Obstet Gynecol; 1984 Oct; 64(4):564-72. PubMed ID: 6207473
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
[TBL] [Abstract][Full Text] [Related]
29. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients.
Shinozuka T; Miyamoto T; Muramatsu T; Hirasawa T; Murakami M; Makino T; Tanaka Y
Cancer; 1999 Apr; 85(7):1555-64. PubMed ID: 10193946
[TBL] [Abstract][Full Text] [Related]
30. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
32. Mucinous tumors of the ovary. A clinicopathologic study of 70 cases.
Chaitin BA; Gershenson DM; Evans HL
Cancer; 1985 May; 55(9):1958-62. PubMed ID: 2983869
[TBL] [Abstract][Full Text] [Related]
33. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture.
Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Suzuki T; Ino K; Kawai M; Mizutani S
Oncology; 2003; 65(1):29-36. PubMed ID: 12837980
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
Sabatier R; Calderon B; Lambaudie E; Chereau E; Provansal M; Cappiello MA; Viens P; Rousseau F
Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
[TBL] [Abstract][Full Text] [Related]
35. Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
Hoogland H; Blijham G; Bron H; Eekhout A; van Geuns H; Haest J; Huiskes H; Kornman J; de Koning Gans H; Lalisang F
Prog Clin Biol Res; 1985; 201():213-5. PubMed ID: 3841592
[No Abstract] [Full Text] [Related]
36. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
[TBL] [Abstract][Full Text] [Related]
37. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
Rose PG; Faulhaber P; Miraldi F; Abdul-Karim FW
Gynecol Oncol; 2001 Jul; 82(1):17-21. PubMed ID: 11426956
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer].
Hernádi Z; Juhász B; Póka R; Mahunka I; Lampé L
Orv Hetil; 1987 Nov; 128(47):2457-61. PubMed ID: 3320851
[No Abstract] [Full Text] [Related]
39. Early stage mucinous ovarian cancer: A review.
Crane EK; Brown J
Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
[TBL] [Abstract][Full Text] [Related]
40. Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases.
Guerrieri C; Högberg T; Wingren S; Fristedt S; Simonsen E; Boeryd B
Cancer; 1994 Oct; 74(8):2329-40. PubMed ID: 7922984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]